The enthusiasm for the research and development of new Chinese medicines is high, and many pharmaceutical companies have submitted clinical applications since the second half of the year!

[Pharmaceutical Network Industry News] Recently, another pharmaceutical company has submitted a clinical application for new Chinese medicine! According to the news, Jianmin Pharmaceutical Group submitted a clinical application for Tongjiang Granules, which is a new type of Chinese medicine 1 dru.
According to the data, Tongjiang granules are mainly used for the treatment of gastroesophageal reflux diseas.
The company said that after the development of this product is completed, it will help to supplement the company's characteristic traditional Chinese medicine varieties and enrich the company's product lin.
According to the data of Mine.
com, the total market size of Chinese patent medicine gastric medicine (gastritis, ulcer) in the three major terminals and six major markets in 2021 has exceeded 10 billion yua.
Among them, the terminals of public medical institutions in China are the main sales position.
However, in recent years, with the online sales of prescription drugs Actively advancing, the sales of online pharmacy terminals are also rapidly increasing, with a growth rate of 69% in 2021, and the future market potential is hug.
Since the second half of this year, the enthusiasm for the research and development of new traditional Chinese medicines has remained the sam.
In addition to Jianmin Pharmaceutical, many pharmaceutical companies have submitted clinical applications for new traditional Chinese medicine.
Kangmin Zhenke Granules and other varieties, in addition, Jishengtang Pharmaceutical's 3 new traditional Chinese medicine drug Shuganjieyu Capsules has also recently submitted a clinical applicatio.
Class 1 new drugs of traditional Chinese medicine are entering a blowout perio.
According to the "2021 National Blue Book of Traditional Chinese Medicine Supervision", in 2021, China will approve 12 new Chinese medicine drugs, which has exceeded the sum of the past four year.
At the same time, the Blue Book pointed out that in recent years, the ability of traditional Chinese medicine to inherit and innovate has been significantly enhanced, and the number of applications for new Chinese medicine clinical trials and new drug marketing authorization applications has increased year by yea.
Among them, in terms of new drug clinical trials, there will be 78 traditional Chinese medicines in 2021, an increase of 14% over 2020.And the indications of these clinical trials are mainly concentrated in the fields of neuropsychiatry, digestion, and respiratio.
Behind the active research and development of new drugs by pharmaceutical companies, policy support is inseparabl.
In recent years, a series of favorable policies for traditional Chinese medicine have been continuously introduce.
For example, the approval of new traditional Chinese medicines has been accelerated, and the evaluation and approval of new traditional Chinese medicines with human experience has been optimize.
Tongfang Yao, et.
, to study the management mechanism for exempting non-clinical safety research and some clinical trials in accordance with laws and regulations; the 2020 new version of the traditional Chinese medicine registration management method divides traditional Chinese medicines into four categories, including category 1 innovative TCM drugs and category 2 improved TCM new drugs , 3 kinds of ancient classical famous prescriptions of traditional Chinese medicine compound preparations and 4 kinds of drugs with the same name with the same name, to further encourage the research and development of new traditional Chinese medicine.
At the same time, the centralized procurement of proprietary Chinese medicines is constantly approaching, forcing pharmaceutical companies to speed up innovation and upgrading, and actively invest in the research and development of new Chinese medicines, and the research and development results are becoming more and more fruitfu.
It is worth mentioning that, compared with chemical drugs and biological drugs, traditional Chinese medicines will encounter many challenges in the research and development process due to their complex properties, including the need to form a new research model for new registration classifications, and how to carry out patient-centered research on traditional Chinese medicine.
Research and development, basic problems and reconciliation of new Chinese medicine researc.
In addition, in clinical application, how to elucidate Chinese patent medicines with modern medicine is also a big challenge due to unclear effective substances, unclear mechanism of action and dose-effect, and insufficient evaluation of clinical effectivenes.
The industry believes that the research and development of new traditional Chinese medicines needs to be patient-centered and clinical value-oriente.
"New traditional Chinese medicines developed from clinical needs will be more competitiv.
" Disclaimer: In any case, the information or expressions in this article opinions, and do not constitute investment advice to anyon.